INXN 2001

Drug Profile

INXN 2001

Alternative Names: Ad-IL-12; Ad-RTS-hIL-12; Ad-RTS-IL-12; Ad-RTS-mIL-12; Adenoviral-vector-interleukin-12-gene-therapy-ZIOPHARM-Oncology; INXN2001; ZIN-ATI-001

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZIOPHARM Oncology
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Glioma
  • Suspended Malignant melanoma
  • Discontinued Colorectal cancer

Most Recent Events

  • 20 Nov 2017 Efficacy data and adverse events data from a phase I trial in Glioma released by company
  • 16 Oct 2017 Phase-I clinical trials in Glioma (In adolescents, In children, In infants, In neonates, Combination therapy, Second-line therapy or greater) in USA (Intratumoural) before October 2017
  • 06 Jun 2017 Adverse event data from a phase I trial in Glioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top